Cypress Capital Group’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $424K | Hold |
2,000
| – | – | 0.04% | 223 |
|
|
2026
Q1 | $392K | Hold |
2,000
| – | – | 0.04% | 193 |
|
|
2025
Q4 | $347K | Sell |
2,000
-48
| -2% | -$8.74K | 0.04% | 194 |
|
|
2025
Q3 | $390K | Buy |
2,048
+48
| +2% | +$8.52K | 0.05% | 182 |
|
|
2025
Q2 | $359K | Hold |
2,000
| – | – | 0.04% | 179 |
|
|
2025
Q1 | $338K | Sell |
2,000
-190
| -9% | -$31.2K | 0.04% | 171 |
|
|
2024
Q4 | $330K | Sell |
2,190
-1,566
| -42% | -$244K | 0.04% | 220 |
|
|
2024
Q3 | $583K | Sell |
3,756
-78
| -2% | -$11.6K | 0.07% | 210 |
|
|
2024
Q2 | $525K | Buy |
3,834
+1,648
| +75% | +$226K | 0.06% | 206 |
|
|
2024
Q1 | $291K | Sell |
2,186
-1,611
| -42% | -$209K | 0.03% | 254 |
|
|
2023
Q4 | $524K | Hold |
3,797
| – | – | 0.07% | 216 |
|
|
2023
Q3 | $463K | Sell |
3,797
-1,340
| -26% | -$179K | 0.07% | 218 |
|
|
2023
Q2 | $722K | Sell |
5,137
-1
| -0% | -$138 | 0.1% | 185 |
|
|
2023
Q1 | $727K | Sell |
5,138
-3,688
| -42% | -$528K | 0.11% | 175 |
|
|
2022
Q4 | $1.38M | Buy |
8,826
+273
| +3% | +$39.2K | 0.21% | 107 |
|
|
2022
Q3 | $1.05M | Buy |
8,553
+4
| +0% | +$527 | 0.17% | 122 |
|
|
2022
Q2 | $1.14M | Sell |
8,549
-52
| -0.6% | -$7.09K | 0.17% | 118 |
|
|
2022
Q1 | $1.18M | Buy |
8,601
+109
| +1% | +$15.2K | 0.15% | 134 |
|
|
2021
Q4 | $1.47M | Sell |
8,492
-78
| -0.9% | -$11.9K | 0.18% | 106 |
|
|
2021
Q3 | $1.25M | Buy |
8,570
+4,750
| +124% | +$695K | 0.17% | 122 |
|
|
2021
Q2 | $504K | Sell |
3,820
-29
| -0.8% | -$3.8K | 0.07% | 207 |
|
|
2021
Q1 | $494K | Sell |
3,849
-2,581
| -40% | -$318K | 0.07% | 208 |
|
|
2020
Q4 | $767K | Sell |
6,430
-2,611
| -29% | -$318K | 0.12% | 150 |
|
|
2020
Q3 | $1.03M | Buy |
9,041
+1,216
| +16% | +$144K | 0.17% | 122 |
|
|
2020
Q2 | $892K | Buy |
7,825
+3,605
| +85% | +$382K | 0.16% | 125 |
|
|
2020
Q1 | $339K | Buy |
4,220
+850
| +25% | +$88K | 0.08% | 155 |
|
|
2019
Q4 | $360K | Hold |
3,370
| – | – | 0.06% | 187 |
|
|
2019
Q3 | $361K | Buy |
3,370
+90
| +3% | +$9.24K | 0.07% | 187 |
|
|
2019
Q2 | $334K | Sell |
3,280
-215
| -6% | -$20.7K | 0.07% | 188 |
|
|
2019
Q1 | $314K | Buy |
+3,495
| New | +$303K | 0.06% | 200 |
|
|
2018
Q2 | – | Sell |
-2,050
| Closed | -$205K | – | 227 |
|
|
2018
Q1 | $205K | Buy |
+2,050
| New | +$210K | 0.04% | 208 |
|
Other funds holding DGX
DSA
Cypress Capital Group's DGX Position: Q2 2026 in Review
Cypress Capital Group held its Quest Diagnostics (DGX) position steady in Q2 2026 at 2,000 shares worth $424K. The position accounts for 0.04% of the portfolio, ranked #223.
Cypress Capital Group first reported a position in DGX in Q1 2018 and has held it in 31 quarters since. The position peaked at $1.47M in Q4 2021. 807 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Cypress Capital Group held 2,000 shares of Quest Diagnostics worth $424K as of Q2 2026.
- Cypress Capital Group left its Quest Diagnostics share count unchanged in Q2 2026.
- Quest Diagnostics made up 0.04% of Cypress Capital Group's portfolio in Q2 2026, its #223 holding.
- Cypress Capital Group first reported a position in Quest Diagnostics in Q1 2018 and has held it in 31 quarters since.
- Cypress Capital Group's Quest Diagnostics position peaked at $1.47M in Q4 2021.
- 807 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Cypress Capital Group's 13F filing for Q2 2026, filed 5 Aug 2026.